M. Cavassini

Discipline

Psychology (14) Economies and finances (12) Sociology (11) Biological anthropology (7) Demography (4) Management (1)

Type

Articles (207) Reviews (16) Conferences and symposiums (4)

Co-author

Date

Source

Keyword

Treatment (136) Human beings (124) therapy (118) Therapeutics (118) cohort (116) Patients (113) Patients (111) Swiss (105) Infection (76) virus (73) infection (73) Older people (71) Immunodeficiency (66) adult (63) adult (63) Population (62) Risk (60) Persons (60) risk (59) Methods (58) Population (58) Methods (58) time (56) Time (56) Ci (Chinese poetry) (55) Analysis (54) art (53) analysis (53) Art (53) Art (53)

Documents written by M. Cavassini (211) | is about M. Cavassini (0)

Randomised, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.
R. Audran et al.
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV.
P. Thoueille et al.
Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy: the SIMPL'HIV open-label, factorial randomised controlled trial.
A. Marinosci et al. (Apr 15, 2024)
Prophylaxie pré-exposition au VIH : les médecins ne sont pas préparés [HIV pre-exposure prophylaxis: physicians are not prepared]
M. Badoux et al. (Apr 10, 2024)
Population pharmacokinetic analysis of doravirine in real-world people with HIV.
P. Thoueille et al.
The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers.
X. Lian et al. (Feb 20, 2024)
Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures.
P. Thoueille et al.
Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.
L. Begré et al.
Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data.
M. Berton et al. (Jan 25, 2024)
Estimation of Improvements in Mortality in Spectrum Among Adults With HIV Receiving Antiretroviral Therapy in High-Income Countries.
A. Trickey et al. (Jan 1, 2024)
Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study.
L. Baumann et al.
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.
P. Thoueille et al.
Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus in Switzerland.
M. Zeeb et al. (Nov 11, 2023)
Remise des autotests VIH en pharmacie d’officine. État des lieux et recommandations de pratique pour une collaboration interprofessionnelle [HIV self-tests in community pharmacies Inventory and practice recommendations for interprofessional collaborations]
M. Rousseau et al. (Oct 25, 2023)
Lymph node dendritic cells harbor inducible replication-competent HIV despite years of suppressive ART.
R. Banga et al. (Oct 11, 2023)
Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018.
B. Jaha et al. (Sep 5, 2023)
Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor-containing regimen.
C. Marzolini et al.
Sexual Behaviour and STI Incidence in Sexually Active MSM Living With HIV in Times of COVID-19.
C. Mugglin et al.
Cerebrospinal Fluid HIV-1 Escape in Patients With Neurocognitive Symptoms: Pooled Data From a Neuro-HIV Platform and the NAMACO Study.
P. Filippidis et al. (Jul 1, 2023)
Leukocyte Count and Coronary Artery Disease Events in People With Human Immunodeficiency Virus: A Longitudinal Study.
E.F. Avery et al. (Jun 8, 2023)
Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration.
P. Thoueille et al. (Jun 1, 2023)
One for all, all for one: neuro-HIV multidisciplinary platform for the assessment and management of neurocognitive complaints in people living with HIV.
J. Damas et al.
Comparison of five different risk scores to predict incident type 2 diabetes in the Swiss HIV cohort study.
F. Blondet et al. (May 1, 2023)
Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years.
I.C. Schoepf et al.
Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic Suppression.
M. Morrow et al.

next